btk inhibitor17

BTK inhibitor 17 is a potent irreversible Bruton’s tyrosine kinase (BTK) inhibitor with an IC50 value of 2.1 nM, suitable for use in rheumatoid arthritis studies.

BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.

P-gp Inhibitor 17 (compound 2g), a potent inhibitor, directly interacts with the transmembrane domain of P-gp. This compound is useful for studying P-gp-mediated multidrug resistance in tumor cells [1].

BTK inhibitor 19 is a highly selective, covalent BTK inhibitor (IC 50 = 2.7 nM).

BRD4 Inhibitor-17 (Compound 5i) is a highly potent inhibitor of BRD4 with an IC50 value of 0.33 μM, playing a crucial regulatory role in transcription by modulating the expression of inflammatory, proliferation, and cell cycle genes. It also shows potential as a remedy for arsenical-induced toxicity [1].

BTK inhibitor 20 is a potent BTK inhibitor with an IC [50 ] of 8 nM.

Btk Inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.

Btk inhibitor 1 Hcl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.IC50 value:Target: BtkFrom PCT Int. Appl. (2012), WO 2012158843 A2 20121122. [1]. PCT Int. Appl. (2012), WO 2012158843 A2 20121122.

BTK inhibitor 13 (compound 8) is a potent and selective BTK inhibitor with an IC50 of 1.2 nM.

HIV-1 inhibitor-18 is a potent inhibitor of the HIV-1 capsid and is able to act on the HIV-1 NL4-3 strain (EC50: 2.57 μM). HIV-1 inhibitor-18 exhibits some cytotoxicity with an MT-4CC50 value of >8.55.

GSK-3β Inhibitor 17 (compound 5 n) reduces the expression of p-p65 and KIM-1 proteins in a dose-dependent manner (16, 32, 64 µM) induced by cisplatin. Additionally, at a concentration of 32 µM, it decreases the levels of TNF-α, IL-1β, IL-6, and MCP-1 mRNA in an acute kidney injury (AKI) model of HK-2 cells triggered by cisplatin.

ATX inhibitor 17, a powerful ATX inhibitor, exhibits an IC50 value of 0.019 µM, demonstrating significant anti-proliferative effects in breast cancer cells.

BTK-IN-17 is a selective, orally active inhibitor of Bruton's Tyrosine Kinase (BTK) with an inhibition concentration (IC50) value of 13.7 nM. It effectively reduces the expression of phosphorylated BTK at Tyrosine 223 (p-BTK Y223) and phosphorylated Phospholipase C Gamma 2 at Tyrosine 1217 (p-PLCγ2 Y1217), demonstrating anti-inflammatory properties.

KRAS G12D Inhibitor 17 (example 8), a quinazoline-linked (4R)-4-hydroxy-L-prolinamide compound, acts as a proteolysis targeting chimera (PROTAC) [1], specifically inducing degradation of the G12D-mutation KRAS protein.

KRAS G12C inhibitor 17 is a potent inhibitor of the KRAS G12C protein.

BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.

KRAS inhibitor-17 (compound 3-9) is a potent inhibitor of KRAS G12C with an IC50 of 3.37 μM. It exhibits p-ERK inhibition with an IC50 of 9.25 μM in MIA PaCA-2 cells and greater than 33.3 μM in A549 cells. KRAS inhibitor-17 has potential applications in the study of pancreatic, colorectal, and lung cancers.

BTK inhibitor 10 is a potent and orally active compound with potential applications in rheumatoid arthritis treatment.

Tubulin inhibitor 17 (Compound 3b) is an inhibitor of tubulin polymerization (IC50 = 12.38 µM) that exhibits anticancer activities and induces cell apoptosis[1].

Mcl-1 Inhibitor 17 is a compound that functions as an inhibitor of the Mcl-1 protein, specifically designed for use in cancer and other disease research [1].

sEH inhibitor-17 (compound 4f) is an orally active soluble epoxide hydrolase (sEH) inhibitor with an IC50 value of 2.94 nM. This compound exhibits anti-inflammatory properties.